Dr. Padmavathi Jonnalagadda, MD

Dr. Jonnalagadda practices at Padmavathi Jonnalagadda,mdpa in Jersey City, New Jersey.

Dr. Jonnalagadda's NPI, 1144228891, was assigned on July 7, 2005. Dr. Jonnalagadda holds New Jersey license 25MA07442900.

Dr. Jonnalagadda's primary practice is Padmavathi Jonnalagadda,mdpa, at 3438 John F Kennedy Blvd, Jersey City, NJ 07307-4166. The practice phone is (201) 420-0366.

Dr. Jonnalagadda's primary practice is Padmavathi Jonnalagadda,mdpa in Jersey City, New Jersey. Dr. Jonnalagadda is also affiliated with The Valley Hospital. The medical group on file is Padmavathi Jonnalagadda MD. Dmand AI also links Dr. Jonnalagadda to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jonnalagadda practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Jonnalagadda's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Jonnalagadda's licenses on file in 2 states: New Jersey and New York.

CMS data shows 51 Medicare services from Dr. Jonnalagadda across 2 procedure codes in 2024, for 59 Medicare patients. Medicare paid $6,310 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 59 Medicare patients who saw Dr. Jonnalagadda in 2024. The largest group is 85 and over, with 22 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jonnalagadda's median patient age at 48, with 49% women.

In 2024, Dr. Jonnalagadda wrote 525 Medicare Part D claims for 45 patients. 81% of them were for generic drugs. CMS names the drug for 267 of them, across 13 drugs with 11 or more claims each, at $9,035 in total drug cost. In 2023, CMS named 485 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Jonnalagadda for performance year 2024, reported through an alternative payment model (APM). Dr. Jonnalagadda accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Dr. Jonnalagadda from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Steris Corporation paid the most, $158.